| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This report provides a complete insight to the technology, companies and
research institutions that are driving this high-growth and promising sector.
Providing...
- A review of nanomedicine and its role in the anticancer market
- An assessment of the main areas in which it can be applied
- Analysis of 6 current products employing nanotechnology
- A review of the work of 30 companies with products in the pipeline
- A thorough look at current research being conducted at over 30
institutions worldwide
This rapidly-expanding and topical area of research promises better
clinical outcomes, targeted therapies and profits for the industry. But what
is the current state of play and where are the real opportunities emerging?
Diagnosing, treating and tracking the progress of therapies for each type of
cancer that exists has long been a dream among oncologists, and one that has
recently grown closer with developments in genomics, proteomics and cell
biology.
Now, a revolution in nanotechnology is pushing personalised cancer treatment
closer than ever before. Future techniques in medical diagnosis and treatment
have often been the subject of science fiction and fantasy.
What was once literary fantasy is now closer to becoming reality. Nature
already operates at the nanoscale and today we are acquiring an increasingly
profound understanding of natural processes at this scale, enabled by a new
generation of scientific instruments.
To provide industry executives with a comprehensive and easy to read
evaluation of this fast growing area, Espicom Business Intelligence has
published this detailed new 125-page report. Covering every aspect of the
subject from current research to applications, products, future pipeline and
ongoing research, the report provides a complete review of nanomedicine and
its growing importance in the cancer field.
This report provides a complete insight to the technology, companies and
research institutions that are driving this high-growth and promising sector.
TABLE OF CONTENTS
1. Scope of report
2. Executive summary
3. Introduction
- 3.1 Introduction to nanotechnology
- Background to nanotechnology
- Figure 1. Artificial and biological nanostructures
- History of nanotechnology
- Construction of nanotechnologies
- Nanomaterials
- Thin films, layers and surfaces
- Carbon nanotubes
- Figure 2. Atomic structures of CNTs
- Inorganic nanotubes
- Nanowires
- Figure 3. Arrays of uniform zinc oxide nanowires
- Microneedles
- Nanofibres as biomaterials
- Figure 4. Arrays of nanofibres
- Biopolymers
- Nucleic acid lattices and scaffolds
- Figure 5. DNA stick figures
- Micelles
- Figure 6. A schematic of the formation of a micelle
- Liposomes
- Figure 7. Schematic representation of four major liposome types.
- Dendrimers
- Figure 8. The dendritic structure
- Liquid crystals
- Superparamagnetic iron oxide crystals
- Nanoparticles
- Aquasomes (carbohydrate-ceramic nanoparticles)
- Polyplexes/Lipopolyplexes
- Hydrogels
- Fullerenes (carbon 60)
- Figure 9. Structure of a C60 fullerene
- Quantum dots
- Figure 10. Silicon at the nanoscale becomes optically active
- Cantilevers with functionalised tips
- Microchips for drug delivery
- 3.2 Nanomedicine: an offshoot of nanotechnology
- Current and future applications
- Array technologies
- Electronics and information and communication technology (ICT )
- Self-assembly
- Drug delivery
- Drug discovery
- Medical imaging
4. Key opportunities for cancer nanomedicine
- 4.1 Molecular imaging and early detection
- Predicted development scenarios
- 4.2 In vivo imaging
- Predicted development scenarios
- 4.3 Reporters of efficacy
- Predicted development scenarios
- 4.4 Multi-functional therapeutics
- Predicted development scenarios
- 4.5 Prevention and control
- Predicted development scenarios
- 4.6 Research enablers
- Predicted development scenarios
5. Market future
- 5.1 Research trends and initiatives
- Broad international survey
- Europe
- Asia
- Patents
- 5.2 Technology and challenges
- Standardisation and quality assurance
- Molecular manufacturing
- Figure 11. Future nanoscale machines
- Programmability of nanodevices
- 5.3 Business and regulatory challenges
- Managing interdisciplinary requirements
- Regulation
- Ethics
- Legal
- 5.4 Nanomedicine growth opportunities
- Economic impact
- Drug delivery
- 5.5 Nanomedicine growth restraints
- Toxicology
- Carcinogenicity
- Long-term stability
- Excretion pathways for artificial nanostructures
- Figure 12. Summary of the hypothetical toxicokinetic pathways for
nanoparticles
- Public perception
- 5.6 Time estimates for nano developments
- Table 1. European Technology Platform on Nanomedicine: Nanotechnology
for Health
- 5.7 Key opinions
- Table 2. Time of realisation of nanobiotechnology developments
- Table 3. Prospects of commercialisation index
- Table 4. Limits to commercialisation
- Table 5. Actions needed to foster realisation
- 5.8 Funding
- Table 6. Examples of public funding for R&D in nanoscience and
nanotechnology
- International government spending
- Table 7. Worldwide government funding for nanotechnology R&D
- Figure 13. Worldwide government funding for nanotechnology R&D
- Figure 14. Number of nanocompanies in Europe
- US-focused overview - regional, State and local spending
- Private investment
6. Current progress in cancer nanomedicine
- 6.1 Products on the market
- Table 8. Products currently on the market with oncology applications
- Abraxis BioScience/AstraZeneca - Abraxane
- Gilead Sciences/Diatos - DaunoXome
- Immunicon - CellSearch Circulating Tumor Cell Kit
- Nanosphere - Bio-barcode and Verigene platform
- Ortho Biotech (Johnson & Johnson) - Caelyx/Doxil
- Figure 15. Representation of a STEALTH liposome.
- Zeneus Pharma - Myocet
- 6.2 Products moving to market
- Table 9. Products moving to the market with oncology applications
- Ablynx
- Acusphere
- Advanced Magnetics/Cytogen
- ADVENTRX Pharmaceuticals
- Alnis Biosciences
- Aphios
- Celsion
- Dendritic Technologies/Starpharma
- Flamel Technologies
- INEX Pharmaceuticals
- Insert Therapeutics (Arrowhead Research)
- Figure 17. Structure of IT-101
- Intradigm
- Introgen Therapeutics
- Kereos
- Keystone Nano
- LiPlasome Pharma
- MagForce Nanotechnologies
- Mersana Therapeutics
- Nanobiotix
- NanoCarrier
- Nanolution (Biophan Technologies)
- NanoMed Pharmaceuticals
- Nanospectra Biosciences
- Pro-Pharmaceuticals
- Project BioFinger
- Figure 18. BioFinger: diagnosis tool based on the measurement of
molecular interactions
- pSivida
- OSI Pharmaceuticals
- Spherics
- TransGenex Nanobiotech
- Triton Biosytems
- 6.3 Novel research
- Burnham Institute
- California State University and the Chinese Academy of Sciences
- Clemson University
- Eindhoven University of Technology and University of Bordeaux
- Friedrich Schiller University
- George Mason University and the University of Texas Health Science Center
- Georgia Institute of Technology
- Harvard University
- Johann Wolfgang Goethe University
- Johns Hopkins University
- Korea Advanced Institute of Science and Technology
- Luikov Heath and Mass Transfer Institute
- Massachusetts Institute of Technology (MIT )
- National Institute of Standards and Technology
- Northwestern University
- Oak Ridge National Laboratory
- Ohio State University
- Sandia National Laboratories
- Seoul National University
- Stanford University
- State University of New York and California State University
- The Scripps Research Institute
- Universite Pierre et Marie Curie
- University of California, Berkeley
- University of Delaware
- University of Florida
- University of Medicine and Dentistry of New Jersey
- University of Michigan
- Figure 19. A flexible platform for the detection and treatment of
cancer
- University of Missouri
- University of Santiago de Compostela
- Virginia Commonwealth University
7. Company index
8. Bibliography
9. Glossary
|
